Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

e year to December 31, 2007.

VYVANSE - ADHD

VYVANSE was launched in the US market in July 2007. Product sales for the three months to June 30, 2008 were $65.2 million (2007: $nil) representing a 20% increase compared to sales of $54.4 million in Q1 2008.

Product sales growth was driven by a 15% increase in prescription demand compared to Q1 2008 together with a price increase in May 2008. For the three months to June 30, 2008 VYVANSE's average quarterly market share was 7.4% (Q1 08: 6.1%) of the US ADHD market.

By July 18, 2008 VYVANSE had achieved a US ADHD average weekly market share of 8.2% based on weekly prescription volumes.

DAYTRANA - ADHD

Product sales for the three months to June 30, 2008 were $22.6 million (2007: $19.9 million). Prescriptions declined by 11% from the same period last year due to a reduction in DAYTRANA's average quarterly market share of the US ADHD market to 1.8% (2007: 2.2%).

Despite the decrease in prescriptions compared to 2007, sales of DAYTRANA grew 14% due to higher market growth, lower sales deductions and a price increase in January 2008.

On June 9, 2008 Shire announced a voluntary recall of a limited portion of DAYTRANA patches because certain patches did not meet their release liner removal specifications which may have resulted in some patients and caregivers having difficulties removing the liners. The voluntary recall was not due to safety issues. Shire and Noven Pharmaceuticals Inc. (the manufacturer of DAYTRANA) continue to pursue enhancements to the product and to work closely with the FDA to implement changes that may improve the usability of DAYTRANA. No interruption in the production of DAYTRANA is anticipated.

US oral mesalamine market share

Shire's average quarterly market share of the US oral mesalamine market rose to 27.6% in the three months to June 30, 2008 (2007: 19.9%), driven by the introduction of LIALDA in March 2007. The overall US oral me
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...TOCKHOLM, November 20 Karolinska D...vestment Fund (EIF) has entered into a,co-investme...und will be,managed by Karolinska Development and ...-stage pharmaceutical and medical technology compa... co-investment fund. The agreement,represents EIF,...
(Date:11/19/2009)..., Nov. 19 Danish Prince Joachim in...thanol plant in Kalundborg, Denmark, on Wednesday,...irst and largest 2nd generation ethanol demonstrat...are used in the plant,s innovative process for con...isco, was the first to market with commercial enzy...
(Date:11/19/2009)... Md., Nov. 19 Spherix In...chnology for diabetes therapy, and a provider of t...d, supplement, biotechnology and pharmaceutical co...Annual Meeting of Shareholders. ,, At the meeti... SPEX ) elected the following members to the Board...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies Form In...ordinate Best Practices in Risk Reduction ,Five ... Gene Synthesis Capacity , ...squo;s leading gene synthesis companies today anno...ening protocol to promote biosecurity in the gene ...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...apids, Wis. - Renaissance Learning, Inc. and A... the merger of AlphaSmart with a subsidiary of Ren...eadquartered in Wisconsin Rapids, provides monitor... are designed to track student progress and give c...r U.S. locations and subsidiaries in Australia, Ca...
...Calif. Researchers at the Ludwig Institute for ...-based NimbleGen Systems , have developed a metho... the human genome, according to a study published ...o find within the human genome the protein sequenc...genes that determine how cells in the body as dive...
...Bone Care International for $600 million to Massac...heir operations are immediately being integrated i... BioSurfaces will receive a $250,000 loan from the...ogram to create 5 new jobs and retain others. On...eather data and services for Internet sites and ot...
Other Biology Technology:NimbleGen identifies human genome sequences 2
(Date:11/19/2009)...J., Nov. 19 BIO-key Inte...er in wireless public safety and finger-based biom... Special Shareholder Meeting held today was adjour...m was not present. ,, (Logo: http://www.newsco...e an impressive 99.3% of the 35 million votes cast...
(Date:11/19/2009)...- Purdue University scientists have helped identif...r cell wall development in maize, an effort that e...he biomass best suited for biofuels production. ,...a professor of plant cell biology, published their...l Plant Physiology on Thursday (Nov. 19). They a...
(Date:11/19/2009)...ceives Competitive NIH Director,s T-R01 Award , S...Dark , Dr. Samie Jaffrey, associate professor of... among the first researchers to win a prestigious ...ational Institutes of Health. Dr. Jaffrey and his ...nition technologies that may some day speed up lab...
Breaking Biology News(10 mins):BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3Maize cell wall genes identified, giving boost to biofuel research 2Weill Cornell science briefs: November 2009 2Weill Cornell science briefs: November 2009 3Weill Cornell science briefs: November 2009 4Weill Cornell science briefs: November 2009 5Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment 53250 1Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment 53250 2New Powder Speeds Healing of Difficult Foot Wounds 4798 1New Powder Speeds Healing of Difficult Foot Wounds 4798 2Patient safety advanced by revised heparin standards 53246 1Patient safety advanced by revised heparin standards 53246 2
...laboratory mice show that nighttime exposure to ar...st tumors by suppressing the levels of a key hormo...tended periods of nighttime darkness greatly slowe...might explain why female night shift workers have ...romising new explanation for the epidemic rise in ...
...ce of a placebo effect has heated up over the past...ng immediate physiological responses to placebos. ...e lab and into a clinical trial, showing a discern...icle in the Feb. 1 British Medical Journal. , Whi...ials to test the effectiveness of a new treatment,...
...00 infants published in this week,s New England Jo...ateq demonstrated that it can safely prevent 98 pe...ng that account for 2 million hospital visits and ... one of the largest pre-licensure vaccine clinical...ned by an Eastern Virginia Medical School investig...
Other Biology News:New Research Shows Artificial Light at Night Stimulates Breast Cancer Growth in Laboratory Mice 2New Research Shows Artificial Light at Night Stimulates Breast Cancer Growth in Laboratory Mice 3All placebos not created alike 2New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3
Custom siRNA, HPLC purified, annealed from Ambion
Silencer Validated siRNA 5 nmol from Ambion
Mouse Anti-Cyclophilin D Monoclonal Antibody, Unconjugated, Clone PADZC006 from Invitrogen
Fok I from Promega
Biology Products: